Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event will take place on September 26, 2024.

Amir Inamdar, Cybin's Chief Medical Officer, will be part of a panel discussion titled 'Advancement in Psychedelic Therapies for Neuropsychiatry'. The panel will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET.

Interested parties can access the webcast through a provided link. An archived version of the webcast will also be available on Cybin's investor relations website under the Events & Presentations page.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024.

The panel discussion, titled “Advancement in Psychedelic Therapies for Neuropsychiatry,” will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240924826591/en/

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

When is Cybin participating in the TD Cowen Neuropsychiatry Summit?

Cybin is participating in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024.

What is the topic of the panel discussion featuring Cybin's CMO at the summit?

The panel discussion is titled 'Advancement in Psychedelic Therapies for Neuropsychiatry'.

How can investors access the webcast of Cybin's panel discussion?

Investors can access the live webcast through a link provided by Cybin. An archived version will also be available on the company's investor relations website.

What time is Cybin's panel discussion scheduled for on September 26, 2024?

Cybin's panel discussion is scheduled for 10:00 a.m. ET on September 26, 2024.

Which stock exchanges is Cybin (CYBN) listed on?

Cybin (CYBN) is listed on the NYSE American and Cboe CA exchanges.